China Resources Pharmaceutical Group Ltd.
3320
Hisse Senetlerindeki Sıralama
#4269
China Resources Pharmaceutical Group Limited, an investment holding company,... China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
Hisse Fiyatı
$0.58910029
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$3.70B
Değişim (1 gün)
-2.23%
Değişim (1 yıl)
-3.41%
Ülke
HK
Ticaret China Resources Pharmaceutical Group Ltd. (3320)
Kategori
Healthcare
China Resources Pharmaceutical Group Ltd. (3320) için Faaliyet Marjı
October 2026 itibarıyla Faaliyet Marjı TTM: 4.21%
China Resources Pharmaceutical Group Ltd. şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) 4.21%'dir. 2023 yılı sonunda şirketin faaliyet marjı 4.31% idi.
China Resources Pharmaceutical Group Ltd. için 2013 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
| Yıl | Faaliyet Marjı | Değiştir |
|---|---|---|
| 2026 (TTM) | 4.21% | -10.43% |
| 2024 | 4.70% | 9.05% |
| 2023 | 4.31% | 1.17% |
| 2022 | 4.26% | 8.95% |
| 2021 | 3.91% | -7.57% |
| 2020 | 4.23% | 7.91% |
| 2019 | 3.92% | -28.86% |
| 2018 | 5.51% | 2.42% |
| 2017 | 5.38% | 1.32% |
| 2016 | 5.31% | -1.30% |
| 2015 | 5.38% | -17.48% |
| 2014 | 6.52% | -10.44% |
| 2013 | 7.28% | 0.00% |
Benzer şirketler veya rakipler için Faaliyet Marjı
| Şirket | Faaliyet Marjı | Faaliyet Marjı Farkı | Ülke |
|---|---|---|---|
| 62.34% | -85.19% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 0.77% | -99.82% |
US
|
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.